On Mar. 13, 2020, Roche announced the FDA has issued an Emergency Use Authorization for the cobasﾮ SARS-CoV-2 Test. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria for testing. Hospitals and reference laboratories can run the test on Rocheﾒs fully automated cobasﾮ 6800 and cobasﾮ 8800 Systems, which are widely available in the U.S. and around the world.